Perspective Therapeutics (CATX) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed Perspective Therapeutics (CATX) over the past year, gaining 52.3% versus a loss of 31.1%. Over five years, CATX leads with a -57.1% price change compared with -90.4% for PACB. Pacific Biosciences of California is the larger company by market cap ($724.2 million vs $303.6 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | PACB |
|---|---|---|
| Share price | $2.66 | $2.33 |
| Market cap | $303.64M | $724.24M |
| 1-day change | -1.85% | +1.30% |
| YTD return | -3.27% | +24.60% |
| 1-year return | -31.09% | +52.29% |
| 5-year return | -57.10% | -90.45% |
| EPS (TTM) | $-1.33 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $3.44 |
| 52-week low | $1.96 | $1.07 |
| Distance from 52-week high | -56.82% | -32.27% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +362.03% | +3.00% |
| Average volume | 1.65M | 10.39M |
| Shares outstanding | 114.15M | 310.83M |
| Employees | 163 | 485 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pacific Biosciences of California is about 2.4 times larger than Perspective Therapeutics by market value ($724.24M vs $303.64M).
- PACB has outperformed CATX by 83.4 percentage points over the past year.
- The two companies sit in different sectors: Perspective Therapeutics in Health Care and Pacific Biosciences of California in Healthcare.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Healthcare · Medical Devices · 485 employees
CATX vs PACB FAQ
Which is bigger, Perspective Therapeutics or Pacific Biosciences of California?
Pacific Biosciences of California (PACB) is larger, with a market capitalization of $724.24M compared with $303.64M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or PACB?
PACB returned +52.29% over the past 12 months, compared with -31.09% for CATX (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and Pacific Biosciences of California in the same industry?
No. Perspective Therapeutics is in the Health Care sector, while Pacific Biosciences of California is in Healthcare.